Nanoactive Astaxanthin 472-61-7

5% up by HPLC

Product categories

New Products

Product Details

Product Information

Product name	NanoActive Astaxanthin
CAS No.	472-61-7
Quality Standard	5% by HPLC
Appearance	Reddish to dark red, viscous and transparent liquid
Solubility	Soluble in water and oil, heated to over 40℃, dissolution-rate will be accelerated

COA of NanoActive Astaxanthin

Item	Standards	Results
Color	Redush to dark red	conform
Odor	Characteristic	conform
Aspect	Liquid	conform
PH	5-8	6.53
Aerobic plate	<100CFU/g	conform
Yeast&Molds	<10CFU/g	conform
Escherichia coli presence	Negative	conform
Salmonelia presence	Negative	conform
Concliusion	conforms to standard	conform

Usage

Astaxanthin is a carotenoid that is the highest level of carotenoid synthesis ever discovered. The product, which has the strongest antioxidant capacity in nature, is regarded as the revolutionary product of anti-oxidation in the 21st century.

Astaxanthin has an extra hydroxyl group in its structure compared to caeninone-beta carotene. And the oxygen-containing groups of carbonyl groups, which are polar at both ends and non-polar in the middle of the molecule so that they can be placed across the membrane. The ketone structure of polar part has the strong ability to eliminate free radicals. In addition, the hydrophobic part in the middle of the structure is a conjugate unsaturated double bond chain, which can transfer the free radical high electrons outside the cell to reduce cell damages. More importantly, this antioxidant capacity can suppress pre-inflammatory response which is the nf-kb dependent pathway.

As the king of antioxidants, astaxanthin has been found to have physiological and biological functions with more than 100 types, such as anti-aging, skin health protection, prevention of cardiovascular diseases, inhibition and prevention of diabetes, protecting the eyes and central nervous system, enhancing immunity, relieving sports fatigue, enhancing energy metabolism and inhibiting tumors and so on. It is believed that with the further study and understanding of astaxanthin functions, it will be more widely applied into our daily life.

More and more people will enjoy the benefits of astaxanthin. A large number of human clinical trials have been conducted

Security and effectiveness of astaxathin:

Astaxanthin is a lipid-soluble compound, which is difficult to be absorbed by the skin. NanoActive Astaxanthin, with a particle size of less than 30nm developed by nano-delivery system (NSD), completely solve the problems of dissolution and stability of astaxanthin. that stably wrapped in nano-carriers can greatly increase the absorption efficiency and bioavailability.

Features of NanoActive Astaxanthin:

1. NanoActive Asta has good thermal, pH and shear stability, easy to use.
2. NanoActive Asta has significantly improved the stability and bioavailability of Asta.
3. NanoActive Asta can greatly enhance the absorption.
4. NanoActive Asta is 100 % water soluble and 100% oil soluble (amphipathy) with wide range of application.
5. The raw material of Asta meet the FDA GRAS standard

Product Efficacy in cosmetics of NanoActive Astaxanthin:

1. NanoActive ASTA can increase the antioxidant effect of skin cells, protect skin damage from free radicals.
2. NanoActive ASTA is an active ingredient that can resist wrinkles, be whitening and anti-Aging, moisturizing and increasing skin elasticity etc.

skin moisture, elasticity, fine lines, gloss etc have improved significantly after using Astaxanthin

Recommended Quantity: 1-5%. It is better to use with Resveratrol and other products.
Product storage: Avoid light preservation under 25 ℃

Hot Tags : Nanoactive Astaxanthin Astaxanthin Astaxanthine natural astaxanthin NanoActive asta astaxanthin supplier

Send A Message

Related Products

Nanoactive Soy Isoflavones (ISO) 574-12-9

5% by HPLC

Nanoactive Resveratrol (RES) 501-36-0

5% by HPLC

NANOACTIVE LIFT

99% up

Paroxetine Hydrochloride 78246-49-8

97.5% up by HPLC, EP7.0

cis-4,7,10,13,16,19-Docosahexaenoic acid Algea Oil DHA/Algal Oil DHA 6217-54-5

EPA free; 40% up; 50% up

Liraglutide 204656-20-2

Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage 2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: · Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. · Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). · Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. · Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.